Premium
Transcriptomic analyses suggest that mucopolysaccharidosis patients may be less susceptible to COVID‐19
Author(s) -
Pierzynowska Karolina,
Gaffke Lidia,
Węgrzyn Grzegorz
Publication year - 2020
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1002/1873-3468.13908
Subject(s) - covid-19 , mucopolysaccharidosis , transcriptome , biology , virology , computational biology , medicine , genetics , disease , gene , biochemistry , infectious disease (medical specialty) , gene expression , outbreak
We used transcriptomic (RNA‐seq) analyses to determine whether patients suffering from all types and subtypes of mucopolysaccharidosis (MPS), a severe inherited metabolic disease, may be more susceptible to coronavirus disease 2019 (COVID‐19). The expression levels of genes encoding proteins potentially involved in SARS‐CoV‐2 development were estimated in MPS cell lines. Four genes ( GTF2F2, RAB18, TMEM97 , PDE4DIP ) coding for proteins potentially facilitating virus development were down‐regulated, while two genes ( FBN1 , MFGE8 ), the products of which potentially interfere with virus propagation, were up‐regulated in most MPS types. Although narrowing of respiratory tract and occurrence of thick mucus, characteristic of MPS, are risk factors for COVID‐19, transcriptomic analyses suggest that MPS cells might be less, rather than more, susceptible to SARS‐CoV‐2 infection.